BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Maxim Group Downgrades BioLineRx (BLRX) to Hold
August 12, 2016 6:29 AM EDTMaxim Group downgraded BioLineRx (NASDAQ: BLRX) from Buy to Hold with a price target of $1.00 (from $4.00).
Analyst Jason Kolbert highlighted:
The biotechnology bear market that emerged in 2015 continues to drive an increase in the cost of capital and the dilution that companies face. The net result has been a shift in valuations, particularly for microcap companies, to the low end of the... MoreRoth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO Succession
August 11, 2016 11:46 AM EDTRoth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q2 results and appointment of a new CEO, as announced early Thursday.
Analyst Joseph Pantginis commented, The company has several important catalysts slated by year-end, which should be able to address the recent... More
BioLineRx (BLRX) Appoints New CEO
August 11, 2016 6:47 AM EDTBioLineRx Ltd. (Nasdaq: BLRX) announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October 10, 2016.
Mr. Serlin joined the Company in 2009 as its Chief Financial and Operating Officer. He succeeds Kinneret Savitsky, Ph.D., who joined the Company in 2004, and has served as its Chief Executive Officer since 2010. Dr. Savitsky will serve as scientific advisor to the Company through the end of March 2017.
"On behalf of the Board, I would like to thank Kinneret Savitsky for her outstanding leadership and many... More
